Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
ORPHANET |
To investigate the IGHV3-21 frequency and the clinical impact of IGHV3-21 stereotypy, 337 newly diagnosed Swedish CLL patients from a population-based cohort were analyzed.
|
22464020 |
2012 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
ORPHANET |
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.
|
21372840 |
2011 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
ORPHANET |
T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.
|
22875913 |
2012 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
ORPHANET |
Clinically, co-occurrence of SF3B1 mutations and subset 2 BCR configuration prompts disease progression in IGHV3-21-CLL, whereas cooperation between NOTCH1 mutations, +12, and subset 8 BCR configuration invariably primes CLL transformation into Richter syndrome.
|
23637131 |
2013 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.310 |
Biomarker
|
disease |
ORPHANET |
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.
|
21372840 |
2011 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.310 |
Biomarker
|
disease |
ORPHANET |
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
|
23637131 |
2013 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.310 |
Biomarker
|
disease |
ORPHANET |
IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia.
|
22464020 |
2012 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.310 |
Biomarker
|
disease |
ORPHANET |
T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.
|
22875913 |
2012 |
Small Lymphocytic Lymphoma
|
0.300 |
Biomarker
|
disease |
ORPHANET |
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.
|
21372840 |
2011 |
Small Lymphocytic Lymphoma
|
0.300 |
Biomarker
|
disease |
ORPHANET |
T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.
|
22875913 |
2012 |
Small Lymphocytic Lymphoma
|
0.300 |
Biomarker
|
disease |
ORPHANET |
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
|
23637131 |
2013 |
Small Lymphocytic Lymphoma
|
0.300 |
Biomarker
|
disease |
ORPHANET |
IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia.
|
22464020 |
2012 |
Chronic Lymphocytic Leukemia
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL.
|
15466924 |
2005 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
CTD_human |
Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia.
|
15817677 |
2005 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, GEP of 7 homHCDR3 versus 6 nonhomHCDR3-IGHV3-21 CLLs yielded 20 differentially expressed genes, with WNT-16 being that expressed at the highest levels in homHCDR3-IGHV3-21 CLLs.
|
17148579 |
2007 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Scandinavian patients with CLL have shown an overrepresentation of the poor-prognostic IGHV3-21 gene.
|
22464020 |
2012 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
We here investigated the prognostic impact of LPL expression in relation to other prognostic markers including IGHV3-21 usage in 140 CLL patients.
|
19709746 |
2010 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
|
18326815 |
2008 |
Chronic Lymphocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Clinically, co-occurrence of SF3B1 mutations and subset 2 BCR configuration prompts disease progression in IGHV3-21-CLL, whereas cooperation between NOTCH1 mutations, +12, and subset 8 BCR configuration invariably primes CLL transformation into Richter syndrome.
|
23637131 |
2013 |
Chronic Lymphocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A significantly lower usage of IGHV1-69 and IGHV1-2 was documented, with comparable IGHV3-21 frequency (3% Chinese vs 3.8% Italian CLL).
|
26943037 |
2016 |
Chronic Lymphocytic Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Subsets with "CLL-biased" homologous complementarity-determining region 3 (CDR3) were identified: (1) IGKV2-30-IGKJ2, 7 sequences with homologous kappa CDR3 (KCDR3), 5 of 7 associated with homologous IGHV4-34 heavy chains; (2) IGKV1-39/1D-39-IGKJ1/4, 4 unmutated sequences with homologous KCDR3, 2 of 4 associated with homologous IGHV4-39 heavy chains; (3) IGKV1-5-IGKJ1/3, 4 sequences with homologous KCDR3, 2 of 4 associated with unmutated nonhomologous IGHV4-39 heavy chains; (4) IGLV1-44-IGLJ2/3, 2 sequences with homologous lambda CDR3 (LCDR3), associated with homologous IGHV4-b heavy chains; and (5) IGLV3-21-IGLJ2/3, 9 sequences with homologous LCDR3, 3 of 9 associated with homologous IGHV3-21 heavy chains.
|
16076869 |
2005 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Unmutated (UM) immunoglobulin heavy chain variable region (IgHV) status or IgHV3-21 gene usage is associated with poor prognosis in chronic lymphocytic leukemia (CLL) patients.
|
29945996 |
2018 |
Chronic Lymphocytic Leukemia
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we analyzed the global methylation profiles in CLL, by applying high-resolution methylation microarrays (27,578 CpG sites) to 23 CLL samples, belonging to the immunoglobulin heavy-chain variable (IGHV) mutated (favorable) and IGHV unmutated/IGHV3-21 (poor-prognostic) subsets.
|
19897574 |
2010 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL.
|
15466924 |
2005 |
Chronic Lymphocytic Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
A striking exception to this rule was identified in CLL IGHV3-21-expressing cases: one amino acid was deleted from the CDR2 region in 16/63 (25.4%) mutated CLL IGHV3-21 sequences (including public database-derived IGHV3-21 CLL cases + the present series) vs. only 2/257 (0.78%) public database-derived mutated non-CLL IGHV3-21 sequences; 15/16 CLL IGHV3-21 sequences carrying this deletion belonged to a subset with unique, shared HCDR3 and light chain CDR3 motifs.
|
16783849 |
2006 |